Andere Sprachen Syndax Pharmaceuticals, Inc.

Aktien

A2AFL6

US87164F1057

SNDX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.05.2024			% 5 Tage	% 1. Jan.
20,08 ^USD	-0,99 %		-2,81 %	-7,08 %

16.05.	Transcript : Syndax Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:00 AM
15.05.	Syndax Pharmaceuticals, Inc. kündigt Änderungen im Vorstand an	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors	15.05.
Syndax Pharmaceuticals, Inc. Announces Board Changes	15.05.
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference	09.05.
Syndax Pharmaceuticals Q1 Net Loss Widens	08.05.
Syndax Pharmaceuticals : First Quarter 2024 Conference Call	08.05.
Syndax: Q1 Earnings Snapshot	08.05.
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03.05.
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024	01.05.
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum	10.04.
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	09.04.
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	08.04.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05.04.
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	28.03.
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia	27.03.
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment	26.03.
Syndax Says Revumenib NDA Granted FDA Priority Review	26.03.
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia	26.03.
Sector Update: Health Care Stocks Rise Monday Afternoon	18.03.
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer	18.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Syndax Pharmaceuticals, Inc.

Aktien

A2AFL6

US87164F1057

SNDX

Andere Sprachen

Filter